Pharmacological Trials in Migraine: It's Time to Reappraise Where the Headache Is and What the Pain Is Like
Author:
Affiliation:
1. Headache and Pain Unit; Department of Neurological, Motor and Sensorial Sciences; IRCCS San Raffaele Pisana; Rome Italy
Publisher
Wiley
Subject
Clinical Neurology,Neurology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/head.12498/fullpdf
Reference16 articles.
1. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010;Vos;Lancet,2012
2. The International Classification of Headache Disorders, 3rd edition (beta version);Headache Classification Committee of the International Headache Society (IHS);Cephalalgia,2013
3. The neurobiology of vascular head pain;Moskowitz;Ann Neurol,1984
4. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater;Buzzi;Br J Pharmacol,1990
5. OnabotulinumtoxinA for treatment of chronic migraine: Pooled analyses of the 56-week PREEMPT clinical program;Aurora;Headache,2011
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world;Journal of Neurology, Neurosurgery & Psychiatry;2024-05-22
2. OnabotulinumtoxinA: Discussion of the evidence for effectiveness of OnabotulinumA and its place in chronic migraine treatment;Handbook of Clinical Neurology;2024
3. Late Response to Anti-CGRP Monoclonal Antibodies in Migraine;Neurology;2023-09-12
4. Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients;The Journal of Headache and Pain;2022-11-01
5. Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study;European Journal of Neurology;2021-12-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3